Cumberland Pharmaceuticals (CPIX) Upgraded at TheStreet

Cumberland Pharmaceuticals (NASDAQ:CPIX) was upgraded by equities researchers at TheStreet from a “d+” rating to a “c-” rating in a research note issued on Wednesday, April 10th, TheStreetRatingsTable reports.

CPIX traded up $0.18 during trading hours on Wednesday, hitting $5.53. 1,927 shares of the company’s stock were exchanged, compared to its average volume of 8,680. Cumberland Pharmaceuticals has a 1-year low of $4.83 and a 1-year high of $7.00. The stock has a market capitalization of $85.42 million, a price-to-earnings ratio of -46.08 and a beta of 0.28. The company has a current ratio of 2.13, a quick ratio of 1.69 and a debt-to-equity ratio of 0.36.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.24. The firm had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $10.98 million. Cumberland Pharmaceuticals had a negative net margin of 17.09% and a negative return on equity of 3.08%. As a group, research analysts predict that Cumberland Pharmaceuticals will post -0.24 earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Cumberland Pharmaceuticals stock. Stonepine Capital Management LLC raised its position in Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) by 7.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,313,429 shares of the specialty pharmaceutical company’s stock after purchasing an additional 95,028 shares during the quarter. Cumberland Pharmaceuticals comprises approximately 7.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 4th biggest holding. Stonepine Capital Management LLC owned 8.46% of Cumberland Pharmaceuticals worth $7,920,000 at the end of the most recent quarter. 32.30% of the stock is currently owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.

Featured Article: Convertible Shares

Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with's FREE daily email newsletter.